Fred Alger Management, LLC Aerovate Therapeutics, Inc. Transaction History

Fred Alger Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.68 - $29.57 $129,276 - $216,215	7,312 Added 20.04%	43,790 $1.29 Million
Q4 2023 Feb 14, 2024	BUY	$9.58 - $24.25 $112,382 - $284,476	11,731 Added 47.4%	36,478 $825,000
Q3 2023 Nov 14, 2023	SELL	$12.9 - $18.88 $427,338 - $625,437	-33,127 Reduced 57.24%	24,747 $335,000
Q2 2023 Aug 14, 2023	SELL	$15.63 - $22.01 $721,699 - $1.02 Million	-46,174 Reduced 44.38%	57,874 $992,000
Q1 2023 May 15, 2023	SELL	$19.17 - $27.7 $841,697 - $1.22 Million	-43,907 Reduced 29.68%	104,048 $2.1 Million
Q4 2022 Feb 14, 2023	SELL	$15.92 - $30.52 $546,469 - $1.05 Million	-34,326 Reduced 18.83%	147,955 $4.34 Million
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $141,422 - $246,939	9,575 Added 5.54%	182,281 $3.02 Million
Q2 2022 Aug 15, 2022	BUY	$10.8 - $16.91 $61,549 - $96,370	5,699 Added 3.41%	172,706 $2.7 Million
Q4 2021 Feb 14, 2022	BUY	$9.14 - $21.54 $1.53 Million - $3.6 Million	167,007 New	167,007 $1.97 Million

28.4M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $63.6M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.